<DOC>
	<DOCNO>NCT00447694</DOCNO>
	<brief_summary>The purpose trial evaluate change cardiac iron measure MRI T2* beta-thalassemia patient deferasirox treatment .</brief_summary>
	<brief_title>Cardiac T2* Beta-thalassemia Patients Deferasirox Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Male female βthalassemia outpatient chronic transfusion therapy ( define &gt; 8 transfusion per year ) Lifetime minimum 100 previous pack red blood cell transfusion Patients currently chelation therapy require one day wash prior first dose study drug Age ≥ 10 year Sexually active female childbearing potential must negative serum urine pregnancy test use effective method contraception , must undergo clinically document total hysterectomy . Ejection Fraction &lt; 56 % measure use steadystate free precession image MRI Contraindication MRI , include cardiac pacemaker , brain aneurysm clip , implanted neurostimulator , insulin pump , cochlear implant , metal sliver eye , intrauterine device MRI incompatible metal implant intractable claustrophobia Abnormal laboratory value define protocol Clinical laboratory evidence active Hepatitis B Hepatitis C History HIV positive test result ( ELISA Western blot ) Uncontrolled systemic hypertension Second third degree AV block Lifethreatening arrhythmia , include sustain ventricular tachycardia abort sudden death , within last year History cardiac condition unstable cardiac disease control standard medical therapy History clinically relevant ocular toxicity relate iron chelation Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent study treatment Pregnancy breast feeding ( document negative pregnancy test require study entry ) Patients enrol ongoing clinical trial deferasirox ( ICL670 ) withdrawn order participate study Treatment systemic investigational drug within past 4 week topical investigational drug within past 7 day Other surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug History noncompliance medical regimens patient consider potentially unreliable and/or cooperative Other inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron Chelation</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>Chelator</keyword>
	<keyword>Desferal</keyword>
	<keyword>beta-thalassemia</keyword>
	<keyword>Iron overload</keyword>
</DOC>